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ABSTRACT: A de novo ultra-small topology of viral assembly is reported. The design is a tri-
faceted coiled-coil peptide helix, which self-assembles into monodisperse, anionic virions able to 
encapsulate and transfer both RNA and DNA into human cells. Unlike existing artificial systems, the 
virions share the same physical characteristics of viruses being anionic, non-aggregating, abundant, 
hollow and uniform in size, while effectively mediating gene silencing and transgene expression. 
These are the smallest virions reported to date with the ability to adapt and transfer small and large 
nucleic acids thus offering a promising solution for engineering bespoke artificial viruses with 
desired functions. 
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Viruses are hollow nano-shells encasing nucleic acids (NAs).
1
 The shells range from 17 nm (porcine 
cicrovirus)
2
 to 1 µm (pandoravirus),
3
 and all self-assemble from individual protein subunits.
1
 The 
subunits are conserved protein folds programmed to reproduce the viral assembly, which inspires the 
search for synthetic analogues.
4
 Different approaches and chemistries are being proposed, though a 
primary emphasis is often placed on applications rather than the structural cooperativity of viral 
designs.
5-10
 As a result, amorphous, aggregating and polydisperse structures are common products.
10
 
Recent peptide designs offer promising solutions.
11-13
 However, these lack the morphological 
uniformity of viruses, while their ability to infect and mediate genetic processes remains to be 
demonstrated. Here we introduce a de novo self-assembly topology which mitigates these 
shortcomings and provides a biologically functional mimetic of the viral assembly.  
The virus architecture adopts an n-fold rotational symmetry, where n can be 3 or 5 or both.
1
 
Therefore, adapting a virus-like architecture requires a folding unit able to support at least a 
3 
 
symmetric 3D (C3) assembly.
14
 A chemical approach to achieve this using relatively short peptide 
sequences, as opposed to fully folded proteins,
15
 is to template the assembly of a folding unit on a 
macromolecular framework that can support the same properties of symmetry, monodispersity and 
hierarchical assembly. In this light, the dendrimer architecture lends itself as an intrinsic template for 
C3-assembly.
16,17
 Specifically, our design converts dendrimer branching cells, which are covalent 
structures, into supramolecular focal points (Fig 1A).
18
 Introduced as modular nanosphere clusters to 
benefit from monodispersity and dimensional scaling of globular proteins, self-assembling or tecto-
dendrimers are analogous to viral particles in that both assemble from subunits around an inner focal 
point or cavity.
1,19,20
 Thus, utilizing the dendrimer topology in a virus-like design serves the same 
benefits.
 
Figure 1. Tecto-dendrimeric virus-like (TecVir) design. (A). Schematic representation of the 
dendrimer architecture highlighting a branching cell (bold black) in a branch zoomed in for clarity. 
(B) TecVir sequence (top view) and its coiled-coil subunit (lower, left) configured into helical wheels 
with 3.5 residues per turn (lower, right). The subunit (PDB entry 4DMD rendered by PyMOL) 
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highlights a cysteine bridge (yellow). The sequences show heptad repeats of canonical coiled coils, 
designated gabcdef. Residues at a, d sites form the hydrophobic interface, and are isoleucine and 
leucine, respectively, favoring dimer formation. Residues at e and g are anionic glutamates (red) that 
interact with cationic arginines (blue) at c forming intra-helical (g-c) interactions in the same dimer 
and inter-helical (c-e’) interactions between dimers. The arrows indicate intra- and inter-helical 
interactions. (C) Each helix is a branching cell interacting with three other helices giving rise to a 
branching network (left) which closes into a shell (right). 
With this in mind, we designed a tecto-dendrimeric virus-like shell (TecVir). The design is based on 
a self-complementary coiled-coil subunit having three interfacial facets. The subunit is an α-helix 
which self-pairs via a hydrophobic interface typical of a coiled coil dimer (Fig 1B).21 In canonical 
coiled coils each helix has one polar face and one hydrophobic face, which interact with counterpart 
helices, one in dimers and two in higher oligomers.22 By contrast, in this design each individual helix 
has one hydrophobic interface and two polar facets that are arranged to favor interactions with other 
three, but identical, neighbors (Fig 1B&C).23 Thus, each helix can be viewed as a branching cell in a 
continuous branching network whose propagation axis runs perpendicular to that of individual 
helices. All helices pack laterally, which facilitates the closing of an increasingly curved network into 
a shell.14, 23, 24 To support this transition the peptide was extended at the N-terminus with a cysteine-
containing motif CGG (Fig 1 and Table s1 in Supporting Information). The tight inter-helix packing 
is expected to promote proximity-driven oxidation of cysteine residues cementing the structure.25 
Without this cementing effect the C3-symmetric networks would not be complete, resulting in more 
anisotropic assemblies such as nanofibres.13  
Consistent with this, cryogenic transmission electron microscopy (cryo-TEM) revealed abundant and 
monodisperse (12 ± 1.5 nm) spherical shells for TecVir at micromolar concentrations (Fig 2). Small 
angle X-ray scattering (SAXS) was performed to probe the assembly directly in solution. Fitting of 
the SAXS data biased for a co-existence of polydisperse spherical shells with homogeneous 
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cylinders in solution, revealed a dominating external radius of a spherical shell (R1) centered at 6.5 ± 
2.3 nm and a wall thickness (th1) of 4 nm together with an additional R2 of 11.6 ± 5 nm with a th2 of 
5.8 nm (Fig 3A, B, Table s2).26 The values for the two spherical shells overlapped and were in good 
agreement with the cryo-TEM data confirming that the vesicles were largely monodisperse and 
hollow.11,27 The wall thickness matches the span of the coiled-coil building blocks (4-4.4 nm), which 
is indicative of peptides orientating parallel to the axis of rotation in the shells as shown in Figure 
1C. The fitting of the SAXS profile also incorporates a contribution from rod-like 4x2 nm cylinders. 
This finding agrees with the dimensions of individual coiled-coil subunits (4x2 nm)22 that remained 
in equilibrium with the assembled shells (Table s2), which is characteristic of cooperative and 
reversible assemblies.28, 29 
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Figure 2. TecVir assembly. (A) Cryo-electron micrographs of assembled shells, and (B) a 
representative contrast-inverted image analysis (right). (C, D) Cryo-electron tomography (z-planes) 
for TecVir (C) and for TecVir assembled with siRNA (D) at the N/P molar ratio of 1/76 at 100 µM 
peptide, and (E) corresponding iso-surface reconstructions. 
Circular dichroism (CD) spectroscopy confirmed appreciable helix formation for the assembly while 
spectral ∆ε222/∆ε208 ratios were ≥1, as expected for helical oligomers as opposed to monomeric 
helices (Fig 3C, s1A).
30
 The assembly proved to be highly cooperative as gauged by sigmoidal 
unfolding curves with a single transition midpoint (TM) of ~55°C (Fig s1B). Such a stable structure 
was found to be fully reversible with spectra recorded before and after the melt being nearly 
identical. During thermal denaturation (20-90°C) signal intensity at 202 nm remained the same 
providing a clear isodichroic point indicating a two-state transition between helical and unfolded 
forms (Fig s1A). In contrast, an Arg→Ala mutant of the peptide, TecVirala, designed as a negative 
control incapable of self-assembly did not fold or assemble (Fig 3C, s1A and Table s1). TecVir with 
the cysteine residue capped via thioalkylation, TecVir
cap
, did fold, as expected, but the first 
derivatives of its unfolding curves suggested overlapping conformer populations with a predominant 
TM of 65°C (Fig s1C).  
In accord with the data, microscopy revealed co-existent morphological forms: polydisperse particles 
and more anisotropic assemblies, extended nanofibers (Fig s2). This finding is consistent with the 
stabilisation effect of the cysteine residues on the assembly of the coiled-coil networks and with the 
formation of disulphide bridges. Indeed, the comparative quantification of free thiols in TecVir by 
the Ellman’s test gave up to 100% reductions in the concentration of free thiols in the assembly 
confirming that cysteine residues were oxidised. Combined the results indicate that TecVir folds into 
a hierarchical network supporting the formation of homogeneous nanoscale shells.  
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Figure 3. TecVir folding. (A) SAXS profile (grey dots) for TecVir shells and (B) Gaussian 
distributions corresponding to the radii (R) and wall thicknesses (th) of two hollow spheres (blue and 
grey). The fitting curve (dark blue) in A incorporates contributions from the two spheres and a 4x2 
nm cylinder (coiled-coil dimer). (C) CD spectra for TecVir (solid line), TecVircap (dashed line) and 
TecVirala (dotted line): 100 µM peptide, pH 7.4, 10 mM MOPS, 1 mM TCEP (TecVir), 20 °C.  
To function, viral mimetics must infect cells. To gain an insight into its biological relevance, TecVir 
was probed for gene delivery. With the net charge of -3 (Table s1), TecVir assembles into anionic 
shells (ζ-potential of -42.4 ± 0.73, see Supporting Information), which, unlike for most gene-delivery 
agents, disfavours purely electrostatic complexation with negatively charged NAs. Therefore, 
encapsulation is necessary. The free N-terminus of the peptide contributes a positive charge for the 
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coiled-coil units to assemble around NAs, which was envisaged to require low NA-peptide (N/P) 
ratios. Indeed, TecVir co-assembled with small interfering RNA (siRNA) at N/P molar ratios of 
1/40-1/100 promoted appreciable inhibition of targeted gene expression (Fig 4A). At these ratios the 
size of TecVir assemblies increased giving a mean diameter of 26.5 ± 8.7 nm (Fig 2 D, E and Fig 
s3), suggesting the encapsulation of siRNA in TecVir shells. Given that the siRNA duplexes used in 
the study are ~7.5 nm in length (23 bases) and 2 nm (B form) in diameter,
31
 an individual TecVir 
shell has to double in diameter (4 nm) in order to accommodate one or two siRNA duplexes, which 
appeared to be consistent with the overall size increases. 
Figure 4. TecVir biological activity. TecVir-promoted gene transfer, expression (DNA) and 
silencing (siRNA). (A) Knockdown fitness of TecVir and commercial Lipofectamine® RNAiMAX 
and N-TER® (positive controls) normalized against siRNA alone (negative control) and the total 
counts of viable cells at different siRNA/TecVir molar ratios at 37 nM siRNA. (B) Widefield (left), 
fluorescence (middle) and combined (right) micrographs of human dermal fibroblasts transfected 
with plasmid DNA encoding for green fluorescent protein (green). GFP expression measured after 24 
and 48 hours is shown. 
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These siRNA-containing assemblies efficiently transfected cells and mediated gene knockdown 
which was monitored by reverse transcription polymerase chain reaction (RT-PCR) at the mRNA 
level using HeLa cells with two housekeeping genes, ACTB (β-actin, targeted) and GAPDH 
(reference).
32
 The silencing of β-actin mRNA was detected at 24 ± 2 hours and 48 ± 2 hours post-
transfection, with knockdown efficiency being comparable to that of commercial peptide (N-Ter®) 
and liposomal (Lipofectamine® RNAiMAX) reagents (Fig 4A). Higher N/P ratios gave negligible 
knockdown levels, while no obvious increases were observed for lower N/P ratios. By marked 
contrast, siRNA/TecVir complexes that were attempted by adding siRNA into pre-assembled TecVir 
shells failed to yield reproducible knockdown, confirming that co-assembly is necessary for 
encapsulation. 
Monodispersity for viruses is a constraint ensuring the encapsulation of viral genes. Viral capsids 
tend to resist increases in cargo sizes, but may adapt by increasing the outer diameters through capsid 
packing defects.
33
 The TecVir shells are uniform and homogeneous in size, and are also structurally 
adaptable for encapsulating a larger genetic cargo. To test this, TecVir was co-assembled with a 
large plasmid DNA encoding for the enhanced green fluorescent protein (pEGFP) and the obtained 
vehicles were used to transfect primary cells, human dermal fibroblasts (Fig 4B). Strikingly, lower 
N/P molar ratios, as expected for larger NAs, gave transfection efficiencies comparable with those of 
a liposomal reagent Lipofectamine® 2000, while EGFP expression peaked at 80% within 48 hours 
of incubation for both reagents with no apparent changes in cell morphology (Fig 4B and s4A). 
Biological activity (EGFP expression and mRNA silencing) was not associated with cytotoxic 
effects. In addition to unaltered cell morphology during transfections (Fig 4B), cell viability 
AlamarBlue® assays, which provide quantitative indicators of metabolically active cells, revealed 
that TecVir-treated cells remained viable over the entire transfection periods (up to 48 hours) (Fig 
s4B).  
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In summary, by combining the principles of chemical and de novo protein design we have 
engineered self-assembling peptide shells as structural and functional mimetics of viruses. These are 
compact and small nanoshells that can adapt to encapsulate both RNA and DNA. Similar to viruses, 
these shells self-assemble from individual subunits and promote functional gene transfer into live 
cells. Unlike viral subunits, which are large and conserved proteins, TecVir is built of much smaller 
peptides. This is beneficial for the development of bespoke artificial viruses because peptides are 
more synthetically accessible, their chemistry allows substantial orthogonality for topology and 
functionalization, while peptide folding-assembly pathways can be predictably engineered using 
basic protein folding motifs. In functional terms, TecVir forms virus-like nanoshells with pI (4.5) 
that falls within the range of viral isoelectric points of 3.5-7.
34
 This property holds a particular 
promise for engineering small anionic virions with the ability to cross blood brain barrier or 
circumvent rapid clearance from circulation and cytotoxicity, which for cationic reagents remain 
major obstacles towards efficient gene therapy approaches.
35  
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